Literature DB >> 3664513

Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer.

B Hecquet1, P Vennin, C Fournier, B Poissonnier.   

Abstract

cis-Diamminedichloroplatinum (100 mg/m2) was administered to the same patients (n = 9) with advanced uterine cervical tumors, via i.v. and intraarterial (i.a.) (bilateral hypogastric arteries) routes. Measurement of plasma pharmacokinetic parameters enabled us to show up areas under the curve (AUC) of free cis-diamminedichloroplatinum versus time significantly (P less than 0.01) lower after i.a. injection (mean value, 3.9 mg.h/liter) than after i.v. injection (mean value, 5 mg.h/liter). However, the increase in intratumoral concentrations after i.a. administration was only at the limit of statistical significance (P = 0.05). Consequently, the benefit of local i.a. administration, evaluated according to the method of Collins, was small (1.2-2.3). An explanation of the phenomena observed can be given using the generalized compartmental model of Collins. We have demonstrated that the parameters of this model can be entirely calculated by taking into account both the i.v. and i.a. pharmacokinetic measurements. Calculations from experimental data of the model parameters, clearances of the body (ClB), and exchange rate between the site of administration and the rest of the body (Q) were in accordance with the physiological values. On the basis of the parameter values, it was confirmed that the low benefit of i.a. administration was due to the fast blood exchange between the injection site and the rest of the body and the probable cis-diamminedichloroplatinum binding on healthy tissues irrigated by the hypogastric artery.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664513

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Pharmacokinetics of cisplatin given at a daily low dose as a radiosensitiser.

Authors:  G Milano; V Troger; A Courdi; X Fontana; P Chauvel; J L Lagrange
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

Authors:  S S Bielack; R Erttmann; G Looft; C Purfürst; G Delling; K Winkler; G Landbeck
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer.

Authors:  V C Sileni; V Fosser; P Maggian; E Padula; M Beltrame; M Nicolini; P Arslan
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.

Authors:  S L Vaden; P L Williams; R L Page; J E Riviere
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma.

Authors:  William A Michaud; Anthony C Nichols; Edmund A Mroz; William C Faquin; John R Clark; Shahnaz Begum; William H Westra; Hiroshi Wada; Paul M Busse; Leif W Ellisen; James W Rocco
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

6.  Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile.

Authors:  Cinzia Federico; Jennifer Sun; Barbara Muz; Kinan Alhallak; Pippa F Cosper; Naoshad Muhammad; Amanda Jeske; Amanda Hinger; Stephanie Markovina; Perry Grigsby; Julie K Schwarz; Abdel Kareem Azab
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-27       Impact factor: 7.038

7.  Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

Authors:  F J P Hoebers; D Pluim; A A M Hart; M Verheij; A J M Balm; G Fons; C R N Rasch; J H M Schellens; L J A Stalpers; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-18       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.